Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elicio Therapeutics, Inc.ELTX · Entity 299 | Director | August 31, 2026 | September 02, 2026 |
| Gamida Cell Ltd.GMDA · Entity 94655 | Director | January 31, 2024 | February 02, 2024 |
| Neon Therapeutics, Inc.NTGN · Entity 149433 | Director | June 26, 2018 | June 26, 2018 |
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Director | January 25, 2018 | January 29, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elicio Therapeutics, Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-08-31 | Direct | 21,750 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 21,750 · Balance 21,750 F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.
Gamida Cell Ltd.
Report date January 31, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 423,750 |
Reported balance
After 2024-01-31 transaction · row 1
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 200,000 · Balance 423,750 F1: Represents a restricted share unit award, which shall vest on January 31, 2025, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit award, which shall vest on January 31, 2025, subject to the Reporting Person's continuous service through such vesting date.
Neon Therapeutics, Inc.
Report date June 26, 2018 · Filed June 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2028-06-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-06-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: This option shall vest in full on the earlier to occur of the first anniversary of the date of grant or the next annual meeting, subject to continued services as a member of the Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on the earlier to occur of the first anniversary of the date of grant or the next annual meeting, subject to continued services as a member of the Board of Directors through such vesting date.
PALVELLA THERAPEUTICS, INC.
Report date January 25, 2018 · Filed January 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.72 · Expires 2028-01-25 | Direct | 20,000 |
Reported balance
After 2018-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-25 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option will vest in four equal installments on each of March 31, June 30, September 30 and December 31, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in four equal installments on each of March 31, June 30, September 30 and December 31, 2018.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INFINITY PHARMACEUTICALS, INC.
Report date October 31, 2016 · Filed November 02, 2016
Section 16 reporting ended · disclosed 2016-11-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,150 |
Reported balance
After 2016-10-31 transaction · row 1
1 source rowRow 1 · 2016-10-31 · Grant · Acquired 59,150 · Balance 59,150 F1: Represents shares from a grant of performance-based restricted stock on July 22, 2016. Upon the determination by the Compensation Committee of our Board of Directors, such shares vested in full on October 31, 2016. |
| Common StockSEC Table I · non-derivative | IndirectTrust | 262,945 |
Reported balance
Holding disclosure · report date 2016-10-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 262,945 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares from a grant of performance-based restricted stock on July 22, 2016. Upon the determination by the Compensation Committee of our Board of Directors, such shares vested in full on October 31, 2016.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:05 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 21,750 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001230486-26-000002 · wk-form4_1788379523.xml · derivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,750 Underlying: Common Stock · 21,750 shares Expires 2036-08-31 F1 · derivative.exercise_date: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. Read SEC document |
| May 19, 2025 Filed May 20, 2025 16:06 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001601485-25-000087 · wk-form4_1747771603.xml · derivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2035-05-19 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 07:37 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 4,100 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001601485-24-000099 · wk-form4_1732538230.xml · derivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2034-11-21 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 16:42 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002328 · form4-02022024_090215.xml · nonDerivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 423,750 F1 · shares: Represents a restricted share unit award, which shall vest on January 31, 2025, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 17:05 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 4,100 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001140361-23-060234 · form4.xml · derivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2033-12-28 F1 · shares: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 16:22 UTC Amendment | Gamida Cell Ltd. GMDA · Entity 94655 | GrantShare Option (Right to Buy) · Derivative | 56,600 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-053245 · doc4a.xml · derivative · entry 2 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,600 Underlying: Ordinary Shares · 56,600 shares Expires 2033-10-18 F3 · date: The option grant was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023. F4 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 16:22 UTC Amendment | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 28,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-053245 · doc4a.xml · nonDerivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,750 F1 · date: The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023. F2 · shares: Represents an RSU award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 19:21 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantShare Option (Right to Buy) · Derivative | 56,600 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-008537 · doc4.xml · derivative · entry 2 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,600 Underlying: Ordinary Shares · 56,600 shares Expires 2033-02-07 F2 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 19:21 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 28,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008537 · doc4.xml · nonDerivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,750 F1 · shares: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 16:32 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantShare Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-22-058386 · doc4.xml · derivative · entry 2 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Ordinary Shares · 9,500 shares Expires 2032-11-17 F2 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on February 1, 2023, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 16:32 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058386 · doc4.xml · nonDerivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,450 F1 · shares: Represents a restricted share unit award, which shall vest on November 1, 2023, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 27, 2022 Filed Aug 10, 2022 16:58 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantEmployee Share Option (Right to Buy) · Derivative | 291,100 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001209191-22-045234 · doc4.xml · derivative · entry 3 ADAMS JULIAN · CIK 0001230486 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,100 Underlying: Ordinary Shares · 291,100 shares Expires 2032-07-26 F4 · date: The option grant was approved by the Board of Directors of the Issuer on January 28, 2022, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on July 27, 2022. F5 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on July 27, 2023, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 27, 2022 Filed Aug 10, 2022 16:58 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 68,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045234 · doc4.xml · nonDerivative · entry 2 ADAMS JULIAN · CIK 0001230486 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,450 F1 · date: The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on January 28, 2022, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on July 27, 2022. F3 · shares: These shares represent an RSU award, which shall vest in two equal annual installments commencing on December 31, 2022. The vesting of the RSUs is subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 27, 2022 Filed Aug 10, 2022 16:58 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 48,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045234 · doc4.xml · nonDerivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,650 F1 · date: The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on January 28, 2022, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on July 27, 2022. F2 · shares: These shares represent an RSU award, which shall vest in three equal annual installments commencing on July 27, 2023. The vesting of the RSUs is subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 16:40 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001562180-18-000483 · primarydocument.xml · derivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-25 F1 · derivative.exercise_date: The stock option will vest in four equal installments on each of March 31, June 30, September 30 and December 31, 2018. Read SEC document |
| January 25, 2017 Filed Jan 30, 2017 19:04 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0000899243-17-002205 · doc4.xml · derivative · entry 1 ADAMS JULIAN · CIK 0001230486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The stock option will vest in four equal installments on each of March 31, June 30, September 30, and December 31, 2017. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:56 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantCommon Stock | 59,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-032622 · doc4.xml · nonDerivative · entry 1 ADAMS JULIAN · CIK 0001230486 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,150 F1 · shares: Represents shares from a grant of performance-based restricted stock on July 22, 2016. Upon the determination by the Compensation Committee of our Board of Directors, such shares vested in full on October 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.